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Modeling of Pompe Disease using Induced Pluripotent Stem Cells 
for the Development of Novel Therapies
1. Prediction of splicing regulatory elements using in silico tools or minigenes often give false 
positive and false negative results (this thesis). 
2. Assessment of endogenous pre-mRNA splicing is a prerequisite to demonstrate splicing 
modulation in response to gene variants or drug treatment (this thesis).
3. Treatment of skeletal muscle cells in vitro with AONs results in almost complete rescue of the 
IVS1 allele and it provides proof that the concept is sound to be explored in patients (this 
thesis).
4. Differentiation of iPSCs into an expandable and pure precursor population increases 
robustness and simplicity of in vitro disease modeling (this thesis).
5. Isogenic cell lines generated using gene correction are useful for the identification of cellular 
processes related to disorders, and can be used for filtering of genes that are differentially 
expressed due to genetic variation between donors (this thesis).
6. In many ways, the CRISPR story illustrates how science often works, with a fitting reminder that 
the basic microbiological processes driving the survival of bacteria often give rise to valuable 
molecular tools, enzymes and technologies, together with the historical involvement of a 
plethora of unsung heroes whom selflessly advance science for the benefits of humankind 
(Barrangou et al,. Nature Review Microbiology 2017).
7. Unintended uptake and toxicological challenges should be addressed in the very early stages 
of new AON development (adapted from Godfrey et al,. EMBO Molecular Medicine, 2017).
8. iPSCs represent a paradigm shift because they now allow us to directly observe and treat 
relevant patient cells (Shi et al,. Nature Review Drug Discovery 2017).
9. Oligonucleotide therapy does not have the safety and efficacy issues associated with 
expressed-vector gene therapy, and its use in some applications is advancing on the road 
to approval by the Food and Drug Administration (Askari et al,. The New England Journal of 
Medicine 1996).
10. Progress in considering hPSC-derived muscle as a valid source of cells for basic and 
translational research applications has been hindered by the lack of an efficient method to 
isolate muscle precursors (Borchin et al,. Stem Cell Reports 2013).
11. Even if you’re not doing anything wrong, you are being watched and recorded (Edward 
Snowden). 
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